Cargando…
Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
Several studies have examined the clinical benefits of hormone replacement therapy (HRT). However, because long-term use of HRT has been implicated as a risk factor for the development of breast cancer, some women remain skeptical when considering this therapy to address their vasomotor symptoms. He...
Autores principales: | Micha, John P., Rettenmaier, Mark A., Bohart, Randy D., Goldstein, Bram H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Menopause
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452594/ https://www.ncbi.nlm.nih.gov/pubmed/36070869 http://dx.doi.org/10.6118/jmm.21035 |
Ejemplares similares
-
Robotic-Assisted Surgery for the Treatment of Breast and Cervical Cancers
por: Micha, John P., et al.
Publicado: (2022) -
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma
por: Micha, John P., et al.
Publicado: (2022) -
Male Hormonal Contraception: Where Are We Now?
por: Wang, Christina, et al.
Publicado: (2016) -
Metformin and Breast Cancer: Where Are We Now?
por: Cejuela, Mónica, et al.
Publicado: (2022) -
Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)